#1 Clinical Trials Search in Europe

Delafloxacin

Delafloxacin is an investigational antibiotic being studied for its effectiveness in treating various bacterial infections. This article summarizes key findings from clinical trials evaluating delafloxacin for conditions like skin infections, pneumonia, and gonorrhea. We’ll explore how delafloxacin compares to other antibiotics and examine its safety profile across different patient populations.

Table of Contents

What is Delafloxacin?

Delafloxacin is an antibiotic medication that belongs to the fluoroquinolone class of drugs. It is also known by several other names, including RX-3341, ABT-492, ABT-319492, and WQ-3034[1]. In some countries, it is marketed under brand names such as Baxdela, Quofeni, and Delabaxi[1]. Delafloxacin is used to treat various bacterial infections and has been the subject of numerous clinical trials to evaluate its effectiveness and safety.

How Delafloxacin Works

As a fluoroquinolone antibiotic, delafloxacin works by interfering with the bacteria’s ability to replicate their DNA. This action prevents the bacteria from growing and multiplying, ultimately leading to their death. Delafloxacin is effective against a wide range of bacteria, including some that may be resistant to other antibiotics[4].

Conditions Treated by Delafloxacin

Delafloxacin has been studied and used to treat several types of bacterial infections, including:

  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI): This includes conditions such as cellulitis (infection of the deep layers of skin), wound infections, major skin abscesses, and burn-related infections[9][7].
  • Community-Acquired Bacterial Pneumonia (CABP): This is a type of pneumonia that people can get outside of hospitals or healthcare facilities[8].
  • Uncomplicated Gonorrhea: Delafloxacin has been studied for the treatment of this sexually transmitted infection[6].

It’s important to note that delafloxacin is particularly useful in treating infections caused by certain types of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), which is resistant to many common antibiotics[4].

How Delafloxacin is Administered

Delafloxacin can be administered in different ways, depending on the specific condition being treated and the patient’s circumstances:

  • Intravenous (IV) Administration: For severe infections or when patients cannot take oral medications, delafloxacin can be given through an IV line. The typical dose is 300 mg every 12 hours[1][9].
  • Oral Administration: Delafloxacin is also available as tablets for oral use. The usual dose is 450 mg taken every 12 hours[1].
  • Powder for Oral Suspension: A new formulation of delafloxacin as a powder for oral suspension is being studied, which may be particularly useful for patients who have difficulty swallowing tablets[1].

The duration of treatment can vary depending on the type and severity of the infection, but it typically ranges from 5 to 14 days[9].

Clinical Studies and Effectiveness

Numerous clinical trials have been conducted to evaluate the effectiveness of delafloxacin:

  • Skin Infections: In studies comparing delafloxacin to vancomycin (another antibiotic), delafloxacin was found to be equally effective in treating acute bacterial skin and skin structure infections[9][7].
  • Pneumonia: A large study compared delafloxacin to moxifloxacin (another fluoroquinolone antibiotic) in treating community-acquired bacterial pneumonia. The results of this study help determine if delafloxacin is safe and effective for this condition[8].
  • Gonorrhea: A study compared a single oral dose of delafloxacin to a single intramuscular injection of ceftriaxone for treating uncomplicated gonorrhea[6].

These studies have generally shown that delafloxacin is effective against a variety of bacterial infections, including those caused by some antibiotic-resistant bacteria.

Potential Side Effects and Safety Considerations

Like all medications, delafloxacin can cause side effects. Common side effects may include:

  • Nausea
  • Diarrhea
  • Headache
  • Changes in liver function tests

More serious side effects, although rare, can occur with fluoroquinolone antibiotics. These may include tendon problems, nerve damage, and changes in blood sugar levels. Patients should be aware of these potential risks and report any unusual symptoms to their healthcare provider[9].

Drug Interactions

Delafloxacin can interact with other medications. One study specifically looked at the interaction between delafloxacin and midazolam (a sedative medication). This type of study helps doctors understand how delafloxacin might affect the way other drugs are processed by the body[5]. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Use in Special Populations

Research has been conducted to understand how delafloxacin works in people with certain health conditions:

  • Liver Problems: A study examined how delafloxacin is processed in people with various degrees of liver impairment. This information helps doctors adjust the dose if necessary for patients with liver problems[3].
  • Lung Conditions: Another study looked at how delafloxacin is distributed in the lungs. This is particularly important for treating respiratory infections like pneumonia[2].

These studies help ensure that delafloxacin can be used safely and effectively in diverse patient populations.

Aspect Details
Drug Name Delafloxacin (also known as RX-3341, ABT-492, WQ-3034)
Drug Class Fluoroquinolone antibiotic
Formulations Studied Intravenous (IV), oral tablets, oral suspension
Main Indications Acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), uncomplicated gonorrhea
Comparator Drugs Vancomycin, aztreonam, moxifloxacin, ceftriaxone, tigecycline
Key Outcome Measures Clinical response, microbiological response, reduction in lesion size, resolution of symptoms
Safety Assessments Adverse events, clinical laboratory results, vital signs, ECG measurements
Special Populations Studied Patients with hepatic impairment, drug interaction studies

FAQ

  • What is delafloxacin? Delafloxacin is an investigational antibiotic belonging to the fluoroquinolone class. It is being studied for treating various bacterial infections, including skin infections, pneumonia, and gonorrhea.
  • What types of infections is delafloxacin being tested for? Clinical trials are evaluating delafloxacin for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), uncomplicated gonorrhea, and other bacterial infections.
  • How is delafloxacin administered? Delafloxacin is being studied in both intravenous (IV) and oral formulations. Some trials use IV administration followed by a switch to oral tablets, while others test oral suspension or IV-only regimens.
  • How does delafloxacin compare to other antibiotics in clinical trials? Various trials compare delafloxacin to antibiotics like vancomycin, aztreonam, moxifloxacin, and ceftriaxone. Results suggest delafloxacin may be similarly effective for certain infections, but more research is needed to confirm its comparative efficacy and safety.
  • What are some potential side effects of delafloxacin? While specific side effects aren't detailed in the trial summaries, the studies are evaluating the safety and tolerability of delafloxacin. Common antibiotic side effects may include gastrointestinal issues, headache, and skin reactions. Always consult a healthcare provider for medical advice about side effects.

Ongoing Clinical Trials on Delafloxacin

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Serious skin infections caused by bacteria that often require antibiotic treatment.
  • Community-Acquired Bacterial Pneumonia (CABP): A type of pneumonia (lung infection) that is acquired outside of a healthcare setting, typically caused by bacteria.
  • Methicillin-Resistant Staphylococcus Aureus (MRSA): A type of bacteria that is resistant to certain antibiotics, making infections harder to treat.
  • Intravenous (IV): Administered directly into a vein.
  • Oral Suspension: A liquid form of medication that is taken by mouth.
  • Efficacy: The ability of a drug to produce the desired therapeutic effect.
  • Adverse Event (AE): Any undesirable experience associated with the use of a medical product in a patient.
  • Intent-to-Treat (ITT) Population: All participants who are randomized into a clinical trial, regardless of whether they complete the trial or not.

References

  1. https://clinicaltrials.gov/study/NCT06612255
  2. https://clinicaltrials.gov/study/NCT03534622
  3. https://clinicaltrials.gov/study/NCT02245243
  4. https://clinicaltrials.gov/study/NCT00719810
  5. https://clinicaltrials.gov/study/NCT02505997
  6. https://clinicaltrials.gov/study/NCT02015637
  7. https://clinicaltrials.gov/study/NCT01984684
  8. https://clinicaltrials.gov/study/NCT02679573
  9. https://clinicaltrials.gov/study/NCT01283581
  10. https://clinicaltrials.gov/study/NCT01811732